Skip to main content
Log in

Identification of a novel potent, selective and cell permeable inhibitor of protein kinase CK2 from the NIH/NCI Diversity Set Library

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

The anti-apoptotic protein kinase CK2 increasingly becomes an attractive target in cancer research with great therapeutic potential. Here, we have performed an in vitro screening of the Diversity Set III of the DTP program from the NCI/NIH, comprising 1600 compounds. We have identified 1,3-Dichloro-6-[(E)-((4-methoxyphenyl)imino)methyl] dibenzo(b,d) furan-2,7-diol (referred to as D11) to be a potent and selective inhibitor of protein kinase CK2. The D11 compound was tested against 354 eukaryotic protein kinases. By setting the threshold for inhibition to <2 % remaining kinase activity, only DYRK1B, IRAK1 and PIM3 were inhibited to an extent as the tetrameric CK2 holoenzyme and its catalytic subunits α and α′. The IC50 values for the CK2α and CK2α′ were on average 1–2 nM in comparison to the DYRK1B, IRAK1 and PIM3 kinases, which ranged from 18 to 49 nM. Cell permeability and efficacy of D11 were tested with cells in culture. In MIA PaCa-2 cells (human pancreatic carcinoma cell line), the phosphorylation of the CK2 biomarker CDC37 at S13 was almost completely inhibited in the presence of D11. This was observed both under normoxia and hypoxia. In the case of the human non-small cell lung carcinoma cell line, H1299, increasing amounts of D11 led to an inhibition of S380/T382/383 phosphorylation in PTEN, another biomarker for CK2 activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Issinger O-G (1993) Casein kinases: pleiotropic mediators of cellular regulation. Pharmacol Ther 59:1–30

    Article  CAS  PubMed  Google Scholar 

  2. Guerra B, Issinger O-G (1999) Protein kinase CK2 and its role in cellular proliferation, development and pathology. Electrophoresis 20:391–408

    Article  CAS  PubMed  Google Scholar 

  3. Guerra B, Issinger O-G (2008) Protein kinase CK2 in human diseases. Curr Med Chem 15:1870–1886

    Article  CAS  PubMed  Google Scholar 

  4. Duncan JS, Litchfield DW (2008) Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 1784:33–47

    Article  CAS  PubMed  Google Scholar 

  5. Trembley JH, Wang G, Unger G et al (2009) Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 66:1858–1867

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Filhol O, Cochet C (2009) Protein kinase CK2 in health and disease: cellular functions of protein kinase CK2: a dynamic affair. Cell Mol Life Sci 66:1830–1839

    Article  CAS  PubMed  Google Scholar 

  7. Niefind K, Guerra B, Ermakowa I, Issinger O-G (2001) Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme. EMBO J 20:5320–5331

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Ermakova I, Boldyreff B, Issinger O-G, Niefind K (2003) Crystal structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit. J Mol Biol 330:925–934

    Article  CAS  PubMed  Google Scholar 

  9. Bischoff N, Raaf J, Olsen B et al (2011) Enzymatic activity with an incomplete catalytic spine: insights from a comparative structural analysis of human CK2α and its paralogous isoform CK2α’. Mol Cell Biochem 356:57–65

    Article  CAS  PubMed  Google Scholar 

  10. Bischoff N, Olsen B, Raaf J et al (2011) Structure of the human protein kinase CK2 catalytic subunit CK2α’ and interaction thermodynamics with the regulatory subunit CK2β. J Mol Biol 407:1–12

    Article  CAS  PubMed  Google Scholar 

  11. Grankowski N, Boldyreff B, Issinger O-G (1991) Isolation and characterization of recombinant human casein kinase II subunits alpha and beta from bacteria. Eur J Biochem 198:25–30

    Article  CAS  PubMed  Google Scholar 

  12. Valero E, De Bonis S, Filhol O et al (1995) Quaternary structure of casein kinase 2. characterization of multiple oligomeric states and relation with its catalytic activity. J Biol Chem 270:8345–8352

    Article  CAS  PubMed  Google Scholar 

  13. Poole A, Poore T, Bandhakavi S et al (2005) A global view of CK2 function and regulation. Mol Cell Biochem 274:163–170

    Article  CAS  PubMed  Google Scholar 

  14. Niefind K, Issinger O-G (2005) Primary and secondary interactions between CK2alpha and CK2beta lead to ring-like structures in the crystals of the CK2 holoenzyme. Mol Cell Biochem 274:3–14

    Article  CAS  PubMed  Google Scholar 

  15. Olsen BB, Rasmussen T, Niefind K, Issinger O-G (2008) Biochemical characterization of CK2alpha and alpha paralogues and their derived holoenzymes: evidence for the existence of a heterotrimeric CK2alpha- holoenzyme forming trimeric complexes. Mol Cell Biochem 316:37–47

    Article  CAS  PubMed  Google Scholar 

  16. Lolli G, Pinna LA, Battistutta R (2012) Structural determinants of protein kinase CK2 regulation by autoinhibitory polymerization. ACS Chem Biol 7:1158–1163

    Article  CAS  PubMed  Google Scholar 

  17. Schnitzler A, Olsen BB, Issinger O-G, Niefind K (2014) The protein kinase CK2(Andante) holoenzyme structure supports proposed models of autoregulation and trans-autophosphorylation. J Mol Biol 426:1871–1882

    Article  CAS  PubMed  Google Scholar 

  18. Hübner GM, Larsen JN, Guerra B et al (2014) Evidence for aggregation of protein kinase CK2 in the cell: a novel strategy for studying CK2 holoenzyme interaction by BRET(2). Mol Cell Biochem 397:285–293

    Article  PubMed  Google Scholar 

  19. ole-MoiYoi OK, Brown WC, Iams KP et al (1993) Evidence for the induction of casein kinase II in bovine lymphocytes transformed by the intracellular protozoan parasite Theileria parva. EMBO J 12:1621–1631

    CAS  PubMed Central  PubMed  Google Scholar 

  20. Faust M, Montenarh M (2000) Subcellular localization of protein kinase CK2. A key to its function? Cell Tissue Res 301:329–340

    Article  CAS  PubMed  Google Scholar 

  21. Münstermann U, Fritz G, Seitz G et al (1990) Casein kinase II is elevated in solid human tumours and rapidly proliferating non-neoplastic tissue. Eur J Biochem 189:251–257

    Article  PubMed  Google Scholar 

  22. Seitz G, Münstermann U, Schneider HR, Issinger O-G (1989) Characterization of casein kinase II in human colonic carcinomas after heterotransplantation into nude mice. Biochem Biophys Res Commun 163:635–641

    Article  CAS  PubMed  Google Scholar 

  23. Rasmussen T, Skjøth IHE, Jensen HH et al (2005) Biochemical characterization of the recombinant human Drosophila homologues Timekeeper and Andante involved in the Drosophila circadian oscillator. Mol Cell Biochem 274:151–161

    Article  CAS  PubMed  Google Scholar 

  24. Basnet H, Su XB, Tan Y et al (2014) Tyrosine phosphorylation of histone H2A by CK2 regulates transcriptional elongation. Nature 516:267–271

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Sarno S, Pinna LA (2008) Protein kinase CK2 as a druggable target. Mol BioSyst 4:889–894

    Article  CAS  PubMed  Google Scholar 

  26. Niefind K, Yde CW, Ermakova I, Issinger O-G (2007) Evolved to be active: sulfate ions define substrate recognition sites of CK2alpha and emphasise its exceptional role within the CMGC family of eukaryotic protein kinases. J Mol Biol 370:427–438

    Article  CAS  PubMed  Google Scholar 

  27. Boldyreff B, Rasmussen TL, Jensen HH et al (2008) Expression and purification of PI3 kinase alpha and development of an ATP depletion and an alphascreen PI3 kinase activity assay. J Biomol Screen 13:1035–1040

    Article  CAS  PubMed  Google Scholar 

  28. Olsen BB, Wang S-Y, Svenstrup TH et al (2012) Protein kinase CK2 localizes to sites of DNA double-strand break regulating the cellular response to DNA damage. BMC Mol Biol 13:7

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Miyata Y, Nishida E (2008) Evaluating CK2 activity with the antibody specific for the CK2-phosphorylated form of a kinase-targeting cochaperone Cdc37. Mol Cell Biochem 316:127–134

    Article  CAS  PubMed  Google Scholar 

  30. Kuckländer U, Töberich H (1983) Zur Umsetzung von 2-(Aminomethylen)cyclohexanon-derivaten mit dichlorchinonen. Chem Ber 116:152–158

    Article  Google Scholar 

  31. Manning G, Whyte DB, Martinez R et al (2002) The protein kinase complement of the human genome. Science 298:1912–1934

    Article  CAS  PubMed  Google Scholar 

  32. Pagano MA, Bain J, Kazimierczuk Z et al (2008) The selectivity of inhibitors of protein kinase CK2: an update. Biochem J 415:353–365

    Article  CAS  PubMed  Google Scholar 

  33. Götz C, Gratz A, Kucklaender U, Jose J (2012) TF–a novel cell-permeable and selective inhibitor of human protein kinase CK2 induces apoptosis in the prostate cancer cell line LNCaP. Biochim Biophys Acta 1820:970–977

    Article  PubMed  Google Scholar 

  34. Guerra B, Rasmussen TDL, Schnitzler A et al (2015) Protein kinase CK2 inhibition is associated with the destabilization of HIF-1α in human cancer cells. Cancer Lett 356:751–761

    Article  CAS  PubMed  Google Scholar 

  35. Sandholt IS, Olsen BB, Guerra B, Issinger O-G (2009) Resorufin: a lead for a new protein kinase CK2 inhibitor. Anticancer Drugs 20:238–248

    Article  CAS  PubMed  Google Scholar 

  36. Siddiqui-Jain A, Drygin D, Streiner N et al (2010) CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 70:10288–10298

    Article  CAS  PubMed  Google Scholar 

  37. Golub AG, Bdzhola VG, Kyshenia YV et al (2011) Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2. Mol Cell Biochem 356:107–115

    Article  CAS  PubMed  Google Scholar 

  38. Enkvist E, Viht K, Bischoff N et al (2012) A subnanomolar fluorescent probe for protein kinase CK2 interaction studies. Org Biomol Chem 10:8645–8653

    Article  CAS  PubMed  Google Scholar 

  39. Golub AG, Bdzhola VG, Ostrynska OV et al (2013) Discovery and characterization of synthetic 4′-hydroxyflavones-New CK2 inhibitors from flavone family. Bioorg Med Chem 21:6681–6689

    Article  CAS  PubMed  Google Scholar 

  40. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108

    Article  CAS  PubMed  Google Scholar 

  41. Guerra B, Niefind K, Ermakowa I, Issinger O-G (2001) Characterization of CK2 holoenzyme variants with regard to crystallization. Mol Cell Biochem 227:3–11

    Article  CAS  PubMed  Google Scholar 

  42. Pozo N, Zahonero C, Fernandez P et al (2013) Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth. J Clin Invest 123:2475–2487

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Beverly LJ, Starczynowski DT (2014) IRAK1: oncotarget in MDS and AML. Oncotarget 5:1699–1700

    PubMed Central  PubMed  Google Scholar 

  44. Warfel NA, Kraft AS (2015) PIM kinase (and AKT) biology and signaling in tumors. Pharmacol Ther. Epub ahead of print

  45. Le BT, Kumarasiri M, Adams JR et al (2015) Targeting Pim kinase for cancer treatment: opportunities and challenges. Future Med Chem 7(1):35–53

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Tine D. Rasmussen for excellent technical assistance and the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, NCI, USA, for providing us with plated and vialed samples. The Danish Council for Independent Research-Natural Sciences (Grant 1323-00212A to B. Guerra); the Danish Cancer Society (Grant 252-1109-210) and the Danish Research Council (Grant 21-04-0517) to O.-G. Issinger.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Olaf-Georg Issinger.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guerra, B., Hochscherf, J., Jensen, N.B. et al. Identification of a novel potent, selective and cell permeable inhibitor of protein kinase CK2 from the NIH/NCI Diversity Set Library. Mol Cell Biochem 406, 151–161 (2015). https://doi.org/10.1007/s11010-015-2433-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-015-2433-z

Keywords

Navigation